Consistently, passive immunotherapy with antibody targeting the N-terminal projection domain of full-length human tau has shown to be beneficial in Alzheimer’s disease transgenic (Tg) mice by improving the cognitive deficits (Yanamandra et al., 2013; Dai et al., 2015; Subramanian et al., 2017) and blocking the seeding/spreading of tau pathology (Dai et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.